Status:
COMPLETED
A Study Assessing the Efficacy and Safety of CBP-307 in Subjects With Moderate to Severe Ulcerative Colitis (UC)
Lead Sponsor:
Connect Biopharm LLC
Conditions:
Moderate to Severe Ulcerative Colitis
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
This study will evaluate the efficacy and safety of CBP-307 in subjects with moderate to severe ulcerative colitis (UC).
Detailed Description
This is a multicenter, multicountry, randomized, double-blind, placebo-controlled phase II clinical trial to evaluate the efficacy and safety of CBP-307 in subjects with moderate to severe ulcerative ...
Eligibility Criteria
Inclusion
- Main inclusion and exclusion criteria for the study Stage 1:
- Subjects were eligible to be included in the study only if all the following criteria applied:
- Male or female subjects aged 18 to 75 years (inclusive) with a diagnosis of UC established at least 3 months prior to screening by clinical and endoscopic evidence corroborated by a histopathology report;
- Confirmed to have moderately to severely active UC within 14 days prior to the first dose of the investigational product, based on an adapted Mayo score of 4 to 9, and an endoscopic subscore of ≥2;
- Had evidence of UC extending to the rectum with ≥15 cm involvement on endoscopy;
- UC patients who were receiving treatment. Subjects could be enrolled if they met any items below:
- Prior to the randomization visit, subjects had received oral 5-aminosalicylic acid (5-ASA) (e.g., mesalazine, sulfasalazine, olsalazine, balsalazide) for at least 4 weeks with the dose stable for at least 2 weeks;
- Prior to the randomization visit, subjects had received oral or intravenous (IV) corticosteroids e.g. prednisone (daily doses ≤30 mg), budesonide (daily doses ≤9 mg), methylprednisolone (daily doses ≤24 mg), or equivalent dose of corticosteroids for at least 4 weeks, with the dose stable for at least 2 weeks;
- Oral 5-ASA or corticosteroid for treatment of UC had been stopped for at least 2 weeks prior to the screening endoscopy examination which was used for Mayo score assessment;
- A stable dosing regimen had to be used if non-prohibited concomitant medications were used.
- Subjects who met any of the following criteria were excluded:
- Subjects had evidence of toxic megacolon;
- Had subtotal or total colectomy;
- An existing ileostomy, colostomy, or known symptomatic stenosis of the intestine; a history or evidence of adenomatous colonic polyps that had not been removed; a history or evidence of colonic mucosal dysplasia including low or high grade of dysplasia, as well as indeterminate for dysplasia; a suspected or confirmed diagnosis of Crohn's enterocolitis, undiagnosed types of colitis, ischemic colitis, or radiation colitis;
- Previous exposure to lymphocyte-depleting therapies or D-penicillamine, leflunomide; prior exposure to approved or investigational products that inhibited the lymphocyte trafficking;
- Received immunosuppressants within 30 days prior to randomization; received any investigational biologic or non-biologic agent, or approved biologic agent or biosimilars within 60 days or 5 half lives prior to screening (whichever was longer);
- Known active infection during the screening period; treatment for Clostridioides difficile (C. difficile) infection or other intestinal pathogen with 28 days prior to first dose of investigational product; active or latent tuberculosis (TB); Chronic hepatitis B virus (HBV) infection or chronic hepatitis C virus (HCV) infection; any identified congenital or acquired immunodeficiency;
- Received any live vaccine within 30 days prior to screening.
- Main Inclusion and exclusion criteria for subjects' entry into the study Stage 2 from Stage 1:
- Subjects who met all the following criteria entered into the study Stage 2:
- subjects with UC who completed 12 weeks of treatment with CBP-307 or placebo in Stage 1 and completed all the assessments (including colonoscopy) at study visit of Week 12 in study Stage 1;
- Good compliance in Stage 1;
- Subjects or their legal representatives voluntarily signed the ICF for study Stage 2.
- Subjects who met any of the following criteria were excluded from the study Stage 2:
- subjects had any unstable or uncontrolled cardiovascular, pulmonary, hepatic, renal, gastrointestinal, genitourinary, hematological, coagulation, immunological, endocrine/metabolic, or other medical disorder that, in the opinion of the investigator, were to confound the study results or compromise subject safety;
- Allergic to CBP 307 or its excipients, experience of significant adverse events related to the study drug during Stage 1, and not appropriate to participate in Stage 2 assessed by the investigator;
- Active or chronic recurrent infections;
- A history of uveitis or macular oedema.
Exclusion
Key Trial Info
Start Date :
February 27 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 10 2022
Estimated Enrollment :
145 Patients enrolled
Trial Details
Trial ID
NCT04700449
Start Date
February 27 2019
End Date
November 10 2022
Last Update
May 6 2024
Active Locations (66)
Enter a location and click search to find clinical trials sorted by distance.
1
Connect Investigative Site 2316
Phoenix, Arizona, United States, 85018
2
Connect Investigative Site 2308
Mission Hills, California, United States, 91345
3
Connect Investigative Site 2314
Hialeah, Florida, United States, 33016
4
Connect Investigative Site 2309
Homestead, Florida, United States, 33032